Allarity Therapeutics Regains Compliance With NASDAQ Minimum Bid Price Requirement
Allarity Therapeutics Regains Compliance With NASDAQ Minimum Bid Price Requirement
Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that on October 9, 2024, it received a formal notice from The Nasdaq Stock Market, LLC's Office of General Counsel ("Nasdaq"). The notice confirmed that the Company has regained compliance with the minimum bid price requirement as set forth in Nasdaq's Listing Rule 5550(a)(2) (the "Bid Price Rule"). Nasdaq noted that since September 11, 2024, Allarity's stock has maintained a closing bid price of $1.00 or more for 20 consecutive trading days, thereby meeting the requirements for regaining compliance with the Bid Price Rule.
Allarity Therapeutics, Inc.（"Allarity"或"公司"）（纳斯达克：ALLR）是一家临床阶段的药品公司，致力于开发个性化癌症治疗。今天宣布，截至2024年10月9日，收到纳斯达克证券交易所（"纳斯达克"）总法律顾问办公室正式通知。通知确认公司已符合纳斯达克交易所5550(a)(2)上市规则中规定的最低买盘价格要求（"买盘规则"）。纳斯达克指出，自2024年9月11日以来，Allarity的股票已连续20个交易日维持收盘买盘价格为1.00美元或更高，因此满足了买盘规则的符合要求。
